$2.25
+0.01 (+0.45%)
Open$2.28
Previous Close$2.24
Day High$2.32
Day Low$2.21
52W High$3.22
52W Low$0.51
Volume—
Avg Volume281.1K
Market Cap133.52M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,292.9% upside
Current
$2.25
$2.25
Target
$31.34
$31.34
$21.51
$31.34 avg
$48.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 50.02M | 36.25M | 30.93M |
| Net Income | -71,483,302 | -46,622,923 | -5,880,957 |
| Profit Margin | -142.9% | -135.8% | -19.0% |
| EBITDA | -76,418,625 | -52,610,836 | -8,827,347 |
| Free Cash Flow | — | — | -6,633,459 |
| Rev Growth | +38.0% | +38.0% | +18.4% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |